Hepatocellular Carcinoma (HCC): Recent Updates and Evolving Treatment Paradigms - Episode 13

Key Safety Outcomes From Updated Analysis of HIMALAYA Trial in Advanced HCC

R. Katie Kelley, MD, discusses updated safety data on tremelimumab plus durvalumab for patients with advanced hepatocellular carcinoma.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Overview of Hepatocellular Carcinoma (HCC)
    EP. 2: Diagnosing Patients With Hepatocellular Carcinoma
    EP. 3: Factoring Stage and Hepatic Function Into Treatment Decision-Making for HCC
    EP. 4: Treatment Approaches for Patients With Early-Stage HCC
    EP. 5: The Role of Adjuvant Therapy in Patients With Early-Stage HCC
    EP. 6: Updates in First-Line Systemic Therapy for Advanced HCC: The IMbrave150 Trial
    EP. 7: Updates in First-Line Systemic Therapy for Advanced HCC: The HIMALAYA Study
    EP. 8: Optimal Sequencing in Patients With Advanced HCC
    EP. 9: Safety Profiles of Available Therapies in Advanced HCC
    EP. 10: The Future of HCC Treatment
    EP. 11: First-Line Systemic Treatment Options for Patients With Advanced HCC
    EP. 12: Tremelimumab Plus Durvalumab in Patients With Advanced HCC: The HIMALAYA Study
    Now Viewing
    EP. 13: Key Safety Outcomes From Updated Analysis of HIMALAYA Trial in Advanced HCC
    EP. 14: The CELESTIAL Study: Cabozantinib Monotherapy in Advanced HCC Treatment
    EP. 15: Safety and Efficacy Data From the Retrospective Analysis of the CELESTIAL Study in Advanced HCC
    EP. 16: Future of Advanced HCC Treatment
    x